Diagnostic and Predictive Values of IL-6 in a Group of Iraqi Patients with Rheumatoid Arthritis

Abeer Maulan Mohammed; Sarmad Mohammed Zayni; Muhammad M. AL-Anee; Faiq Isho Corial; Adnan Al- Rubaee

doi:10.32007/jfacmedbagdad.2044

Authors

Abeer Maulan Mohammed Ministry of Health, Diyala Teaching Hospital https://orcid.org/0009-0003-3556-309X
Sarmad Mohammed Zayni dept. of microbiology,college of medicine, university of baghdad https://orcid.org/0000-0002-1976-9157
Muhammad M. AL-Anee Dept. of Family and Microbiology, College of Medicine, Baghdad University https://orcid.org/0000-0001-5376-3229
Faiq Isho Corial Department of Medicine, College of Medicine , University of Bagghdad
Adnan Al- Rubaee Dept. of Poultry Science, University of Arkansas, Fayetteville USA

DOI:

https://doi.org/10.32007/jfacmedbagdad.2044

Keywords:

Rheumatoid arthritis (RA) , cytokines, IL6, diagnosis and prediction of RA

Abstract

Background: Researchers have found that interleukin 6 (IL-6) plays a crucial regulatory function in the onset and progression of a wide range of inflammatory disorders. One of the more prevalent inflammatory illnesses affecting people today is rheumatoid arthritis.

Aim of the study: The purpose of this study was to compare the IL-6 levels of rheumatoid arthritis (RA) patients to those of healthy controls and to examine the relationship between IL-6 and RA-related demographic and clinical factors. Materials and Method A total of 80 participants: 40 rheumatoid arthritis (RA) sufferers and 40 healthy controls, all of whom ranged in age from 23 to 61. The serum concentrations of (IL-6) were analyzed using an enzyme-linked immunosorbent assay (ELISA).

Results: Increased IL-6 blood levels were associated with rheumatoid arthritis, suggesting that this biomarker may be useful for diagnosing the disease at an early stage. There was no statistically significant correlation between disease severity and the DAS28 score and IL-6 levels in the serum.

Conclusion: The cytokine interleukin 6 (IL-6) has been proposed as a biomarker and possible player in the etiology of rheumatoid arthritis.

Downloads

Download data is not yet available.

References

McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. The Lancet. 2017 Jun 10;389(10086):2328-37.

Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. In: Seminars in arthritis and rheumatism 2014 Oct 1 (Vol. 44, No. 2, pp. 123-130). WB Saunders.

Calabresi E, Petrelli F, Bonifacio AF, Puxeddu I, Alunno A. One year in review 2018: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2018 May;36(2):175-84.

Di Sante G, Tolusso B, Fedele AL, Gremese E, Alivernini S, Nicolò C, et al. Collagen specific T-cell repertoire and HLA-DR alleles: biomarkers of active refractory rheumatoid arthritis. EBioMedicine. 2015 Dec 1;2(12):2037-45.

Hendler A, Mulli TK, Hughes FJ, Perrett D, Bombardieri M, Houri-Haddad Y, et al. Involvement of autoimmunity in the pathogenesis of aggressive periodontitis. Journal of dental research. 2010 Dec;89(12):1389-94.

Su R, Li Z, Wang Y, Liu Y, Zheng X, Gao C, et al. Imbalance between Th17 and regulatory T cells in patients with systemic lupus erythematosus combined EBV/CMV viraemia. Clinical and Experimental Rheumatology. 2019 Nov 20;38(5):864-73.

Persson GR. Rheumatoid arthritis and periodontitis–inflammatory and infectious connections. Review of the literature. Journal of oral microbiology. 2012 Jan 1;4(1):11829.

Franza L, Carusi V, Altamura S, Gasbarrini A, Caraffa A, Kritas SK, et al. Gut microbiota and immunity in common variable immunodeficiency: Crosstalk with pro-inflammatory cytokines. J. Biol. Regul. Homeost. Agents. 2019 Mar 1;33(2):315-9.

du Teil Espina M, Gabarrini G, Harmsen HJ, Westra J, van Winkelhoff AJ, van Dijl JM. Talk to your gut: the oral-gut microbiome axis and its immunomodulatory role in the etiology of rheumatoid arthritis. FEMS microbiology reviews. 2019 Jan;43(1):1-8.

Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nature medicine. 2015 Aug;21(8):895-905.

Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. Journal of Experimental Medicine. 2020 May 4;217(5).

Pandolfi F, Altamura S, Frosali S, Conti P. Key role of DAMP in inflammation, cancer, and tissue repair. Clinical therapeutics. 2016 May 1;38(5):1017-28.

Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology. 2014 Jul 1;53(7):1321-31..

Matsunami M, Ubara Y, Sumida K, Oshima Y, Oguro M, Kinoshita K, et al. The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome. BMC nephrology. 2018 Dec;19(1):1-5.

Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nature immunology. 2015 May;16(5):448-57.

Narazaki M, Kishimoto T. The two-faced cytokine IL-6 in host defense and diseases. International journal of molecular sciences. 2018 Nov 9;19(11):3528.

Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harbor perspectives in biology. 2014 Oct 1;6(10):a016295..

Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology. 2014 Jul 1;53(7):1321-31.

McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine. 2011 Dec 8;365(23):2205-19.

Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nature Reviews Rheumatology. 2020 Jun;16(6):335-45.

Best JH, Vlad SC, Tominna L, Abbass I. Real-world persistence with tocilizumab compared to other subcutaneous biologic disease-modifying antirheumatic drugs among patients with rheumatoid arthritis switching from another biologic. Rheumatology and Therapy. 2020 Jun;7:345-55.

Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood, The Journal of the American Society of Hematology. 2008 Nov 15;112(10):3959-64.

Abdullah RM, Khalil AA, Jassim NA, Gorial FI. Serum IL17 and IL-6 levels in a Sample of Iraqi Patients with Rheumatoid Arthritis: A Case Control Study. Chemistry and Materials Research. 2013;3(8).

Ibrahim RA, Al-Tae F. Interleukin–6 Serum Level and Single Nucleotide Gene-174 G/C promoter Polymorphism in Patients with Rheumatoid Arthritis/Iraq. Annals of the College of Medicine, Mosul. 2021 Dec 28;43(2):164-75.

Al-Ani MM. Comparison between anti-filaggrin, anti-RA33 and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis in iraqi patients. Iraqi J Comm Med. 2013;3:258-61..

Al-Karkhi MA, AL-Derzi AR, Zeiny SM, Jassim NA, Mahdi BM, Al-Ani MM. Correlation between Anti-infliximab and Anti-CCP Antibodies Development in Patients with Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital. IOSR Journal of Dental and Medical Sciences. 2015;14(11):95-100.

‏